A Phase 1 interventional study of Semaglutide and Cagrilintide in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing cagrilintide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 4 of them phase 3. cagrilintide · Diabetes Mellitus, Type 2.
Among the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2, this one is the 11th largest by enrollment, is one of 6 that started in 2024, is the only one in phase 1, and was the 8th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States, Argentina, Brazil and 7 more countries
Ages 10–18
Novo Nordisk A/S · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, cagrilintide is the treatment under test here. Read study by study →
15 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 6 started in 2024.
This study's enrollment of 158 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 274 across the 15 interventional studies. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 1 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 236th largest by enrollment of the 428 interventional ones that give a count, is one of 26 that started in 2024, is one of 129 in phase 1, and was the 600th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
2 of the studies testing cagrilintide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07817251Phase 3Novo Nordisk A/SResearch Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | 2027-06-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2, from their registry updates:
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This study will look at how CagriSema, semaglutide and cagrilintide regulate insulin effects in the body of people with type 2 diabetes (T2D). CagriSema is a new investigational medicine that combines two medicines called cagrilintide and semaglutide. Doctors may not yet prescribe CagriSema. Participants will either get CagriSema, semaglutide, cagrilintide, or a ''dummy'' medicine. Which treatment the participants will get is decided by chance. Participants will get the study medicine together with the current daily diabetes medicine metformin. Participants should not take other medicines for diabetes during the study. The study will last for about 42 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every 4 weeks in a 16-week dose escalation period until target dose of CagriSema is achieved and maintained for 12 weeks.
Drug: Semaglutide · Drug: Cagrilintide · Drug: Placebo semaglutide · Drug: Placebo cagrilintide
Participants will receive once-weekly s.c injections of semaglutide at escalating doses every 4 weeks in a 16-week dose escalation period until target dose of CagriSema is achieved and maintained for 12 weeks.
Drug: Semaglutide · Drug: Placebo semaglutide
Participants will receive once-weekly s.c injections of cagrilintide at escalating doses every 4 weeks in a 16-week dose escalation period until target dose of CagriSema is achieved and maintained for 12 weeks.
Drug: Cagrilintide · Drug: Placebo cagrilintide
Participants will receive once-weekly s.c injection of placebo matched to semaglutide and cagrilintide for 28 weeks.
Drug: Placebo semaglutide · Drug: Placebo cagrilintide
Participants will receive once-weekly semaglutide subcutaneously.
Participants will receive once-weekly cagrilintide subcutaneously.
Participants will receive once-weekly placebo matched to semaglutide subcutaneously.
Participants will receive once-weekly placebo matched to cagrilintide subcutaneously.
To compare the effect of CagriSema versus placebo: Change in M-value in hyperinsulinaemic euglycaemic clamp (HEC)
M-value from the HEC is calculated from glucose infusion rate (GIR) over the last 30 minutes of the clamp, corresponding to steady state. M-value is defined as: (GIR150-180 min normalised by body weight \[milligram per minute per kilogram {mg/min/kg}\]). Measured in mg/min/kg.
Time frame: Baseline to week 28
To compare the effect of CagriSema versus semaglutide, Semaglutide versus placebo and Cagrilintide versus placebo: Change in M-value in HEC
M-value from the HEC is calculated from GIR over the last 30 minutes of the clamp, corresponding to steady state. M-value is defined as: (GIR150-180 min normalised by body weight \[mg/min/kg\]). Measured in mg/min/kg.
Time frame: Baseline to week 28
To compare the effect of CagriSema versus placebo, CagriSema versus semaglutide, Semaglutide versus placebo and Cagrilintide versus placebo: Change in M-value in HEC, normalised by lean body mass
M-value from the HEC is calculated from GIR over the last 30 minutes of the clamp, corresponding to steady state. M-value is defined as: (GIR150-180 min normalised by body weight \[mg/min/kg\]). Measured in mg/min/kg.
Time frame: Baseline to week 28
Change in first-phase incremental insulin secretion rate (ISR0-8min) in hyperglycaemic clamp (HGC)
Measured in picomoles per minute per square meter (pmol/min/m\^2).
Time frame: Baseline to week 28
Change in second-phase insulin secretion rate (ISR20-120min) in HGC
Measured in pmol/min/m\^2.
Time frame: Baseline to week 28
Change in total insulin secretion rate (ISR0-120min) in HGC
Measured in pmol/min/m\^2.
Time frame: Baseline to week 28
Change in insulin secretion rate at fixed glucose concentration (ISRg) in HGC
Measured in pmol/min/m\^2.
Time frame: Baseline to week 28
Change in total insulin response (total AUC0-120 min) in HGC
Measured in minute \* picomoles per liter (min\*pmol/L).
Time frame: Baseline to week 28
Change in insulin response to arginine (incremental insulin AUCarginine,0-10min) in HGC
Measured in min\*pmol/L.
Time frame: Baseline to week 28
Change in C-peptide response to arginine (incremental insulin AUCarginine,0-10min) in HGC
Measured in min\*nmol/L.
Time frame: Baseline to week 28
Change in clamp disposition index (cDI) calculated from HEC and HGC
cDI is defined as the product of the M-value derived from the hyperinsulinemic euglycemic clamp over the last 30 minutes and total insulin secretion (ISR AUC0-120min) derived from the insulin secretion rate based on C-peptide using the using the deconvolution technique divided by the total glucose AUC0-120min from the hyperglycemic clamp portion of the study. Measured in picomoles \* liter per square meter per square minute per kilogram (pmol\*L/m\^2/min\^2/kg).
Time frame: Baseline to week 28
Change in cDI calculated from HEC and HGC,based on lean body mass
cDI is defined as the product of the M-value derived from the hyperinsulinemic euglycemic clamp over the last 30 minutes and total insulin secretion (ISR AUC0-120min) derived from the insulin secretion rate based on C-peptide using the using the deconvolution technique divided by the total glucose AUC0-120min from the hyperglycemic clamp portion of the study. Measured in pmol\*L/m\^2/min\^2/kg.
Time frame: Baseline to week 28
Change in β-cell glucose sensitivity (insulin secretion) from HGC
Measured in picomoles per minute per square meter per millimoles per liter (pmol/min/m\^2/\[mmol/L\]).
Time frame: Baseline to week 28
Change in β-cell glucose sensitivity from mixed meal tolerance test (MMTT) (slope of dose-response for insulin secretion vs. plasma glucose)
Measured in pmol/min/m\^2/(mmol/L).
Time frame: Baseline to week 28
Change in glucose concentration during MMTT (total and incremental AUC0-300min)
Measured in minute \* millimoles per liter (min\*mmol/L).
Time frame: Baseline to week 28
Change in insulin concentration during MMTT (total and incremental AUC0-300min)
Measured in minute \* picomoles per liter (min\*pmol/L).
Time frame: Baseline to week 28
Change in C-peptide concentration during MMTT (total and incremental AUC0-300min)
Measured in minute \* nanomole per liter (min\*nmol/L).
Time frame: Baseline to week 28
Change in glucagon concentration during MMTT (total and incremental AUC0-300min)
Measured in min\*pmol/L.
Time frame: Baseline to week 28
Change in fasting glucose concentration (MMTT pre-meal concentrations)
Measured in millimole per liter (mmol/L).
Time frame: Baseline to week 28
Change in fasting insulin concentration (MMTT pre-meal concentrations)
Measured in picomole per milliliter (pmol/mL)
Time frame: Baseline to week 28
Change in fasting C-peptide concentration (MMTT pre-meal concentrations)
Measured in nanomoles per liter (nmol/L).
Time frame: Baseline to week 28
Change in fasting glucagon concentration (MMTT pre-meal concentrations)
Measured in picomoles per liter (pmol/L).
Time frame: Baseline to week 28
Change in fasting proinsulin concentration (MMTT pre-meal concentrations)
Measured in pmol/L.
Time frame: Baseline to week 28
Change in HbA1c
Measured as percentage points (%-points).
Time frame: Baseline to week 28
Change in systolic and diastolic blood pressure
Measured in millimeters of mercury (mmHg).
Time frame: Baseline to week 28
Number of Treatment Emergent Adverse Events (TEAEs)
Count of events.
Time frame: Baseline to end of study (week 34)
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Ran from May 2024 to primary completion in Dec 2025, 19 months.
Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 19 months is above that.
Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cagrilintide